Name - Cellectar Biosciences Inc
Current Name: Cellectar Biosciences Inc
Address: 100 Brand Road, Suite 210, Florham Park, NJ 07932
Phone Number: (608) 441-8120
Investor Relations Contact: ir@cellectar.com
Website - https://www.cellectar.com
Warrant Symbol: CLRBW
Warrants Listed: 3,500,000
Ratio: 1-for-1
Cusip Number: 15117F 11 5
Expiry Date - November 20, 2023
xercise Price: $4.50
Synopsis & Listing Information
Cellectar Biosciences is a clinical-stage biopharmaceutical platform developing targeted phospholipid drug conjugates for oncological indications.
Listing History: Warrants were issued through a secondary public capital expansion tranche in November 2018, trading under symbol CLRBW on Nasdaq.
Business Combination: N/A.
Ticker Change: N/A.
Reverse Split Adjustment: Subject to an components-based 1-for-10 reverse split adjustment executed on July 21, 2022.
Current Status: Expired. The warrants reached their definitive expiration terminal on November 20, 2023.
Current Name: Cellectar Biosciences Inc
Address: 100 Brand Road, Suite 210, Florham Park, NJ 07932
Phone Number: (608) 441-8120
Investor Relations Contact: ir@cellectar.com
Website - https://www.cellectar.com
Warrant Symbol: CLRBW
Warrants Listed: 3,500,000
Ratio: 1-for-1
Cusip Number: 15117F 11 5
Expiry Date - November 20, 2023
xercise Price: $4.50
Synopsis & Listing Information
Cellectar Biosciences is a clinical-stage biopharmaceutical platform developing targeted phospholipid drug conjugates for oncological indications.
Listing History: Warrants were issued through a secondary public capital expansion tranche in November 2018, trading under symbol CLRBW on Nasdaq.
Business Combination: N/A.
Ticker Change: N/A.
Reverse Split Adjustment: Subject to an components-based 1-for-10 reverse split adjustment executed on July 21, 2022.
Current Status: Expired. The warrants reached their definitive expiration terminal on November 20, 2023.
American Financial News
Loading the latest American market news...
American Financial News
Loading the latest American market news...